Neutralising effects of small molecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake venoms
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent applications of small molecule inhibitors against medically significant toxins have yielded promising preclinical results and these inhibitors have broad potential as supplemental therapies in combination with standard treatments (37, 49, 50, 51, 52, 53, 54).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [49]
In the citing paper
“Numerous studies have examined the effects of various small molecule inhibitors on the biological activities of venoms in vitro and the neutralization capacity of these inhibitors in vivo (49, 50, 51, 53, 56, 57, 58, 59).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [49]
In the citing paper
“However, thermal-based target deconvolution studies are still suitable for a wide range of unique systems including the study of venom metalloproteins in the presence of chelating agents, for example, DMPS and dimercaprol, both of which have demonstrated therapeutic potential towards treating snakebite (49, 115).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [49]
In the citing paper
“Research on small molecule inhibitors of snake venom toxins has typically focused on in vitro and in vivo functional assays based on the known or likely biological activities of toxins (49, 50, 51, 52, 53, 58, 109, 110, 111, 112, 113).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Causes and Consequences of Snake Venom Variation
Casewell, N. R., Jackson, T. N. W., Laustsen, A. H., & Sunagar, K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.05.006 · Cited by 396
Self-citation
Research works printed but not linked: 58
- Gutiérrez, 2017, Snakebite envenoming, Nat Rev Dis Primers, 3, 1
- Williams, 2019, Strategy for a globally coordinated response to a priority neglected tropical disease: snakebite envenoming, PLoS Neglected Trop Dis, 13, 7059, 10.1371/journal.pntd.0007059 · DOI · Paper page
- Kasturiratne, 2008, The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths, PLoS Med, 5, e218, 10.1371/journal.pmed.0050218 · DOI · Paper page
- Chippaux, 2017, Snakebite envenomation turns again into a neglected tropical disease!, J Venom Anim Toxins incl Trop Dis, 23, 38, 10.1186/s40409-017-0127-6 · DOI · Paper page
- Maduwage, 2014, Current treatment for venom-induced consumption coagulopathy resulting from snakebite, PLoS Neglected Trop Dis, 8, 10.1371/journal.pntd.0003220 · DOI · Paper page
- Slagboom, 2017, Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise, Br J Haematol, 177, 947, 10.1111/bjh.14591 · DOI · Paper page
- Ainsworth, 2018, The paraspecific neutralisation of snake venom induced coagulopathy by antivenoms, Commun Biol, 1, 34, 10.1038/s42003-018-0039-1 · DOI
- Cardoso, 2019, Multifunctional toxins in snake venoms and therapeutic implications: from pain to hemorrhage and necrosis, Front Ecol Evol, 7, 218, 10.3389/fevo.2019.00218 · DOI · Paper page
- de Silva, 2016, Adverse reactions to snake antivenom, and their prevention and treatment, Br J Clin Pharmacol, 81, 446, 10.1111/bcp.12739 · DOI · Paper page
- Morais, 2009, Snake antivenoms: adverse reactions and production technology, J Venom Anim Toxins Incl Trop Dis, 15, 2, 10.1590/S1678-91992009000100002 · doi:10.1590/s1678-91992009000100002
- Habib, 2013, Antivenom therapy of carpet viper (Echis ocellatus) envenoming: effectiveness and strategies for delivery in West Africa, Toxicon, 69, 82, 10.1016/j.toxicon.2013.01.002 · doi:10.1016/j.toxicon.2013.01.002
- Wang, 2018, Exploration of the inhibitory potential of varespladib for snakebite envenomation, Molecules, 23, 391, 10.3390/molecules23020391 · DOI · Paper page
- Bittenbinder, 2018, Coagulotoxic cobras: clinical implications of strong anticoagulant actions of African spitting Naja venoms that are not neutralised by antivenom but are by LY315920 (varespladib), Toxins, 10, 516, 10.3390/toxins10120516 · DOI · Paper page
- Bulfone, 2018, Developing small molecule therapeutics for the initial and adjunctive treatment of snakebite, J Trop Med, 2018, 4320175, 10.1155/2018/4320175 · DOI · Paper page
- Albulescu, 2020, Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite, Sci Transl Med, 12, 10.1126/scitranslmed.aay8314 · DOI · Paper page
- Layfield, 2020, Repurposing cancer drugs batimastat and marimastat to inhibit the activity of a group I metalloprotease from the venom of the Western diamondback rattlesnake, Crotalus atrox, Toxins, 12, 309, 10.3390/toxins12050309 · DOI · Paper page
- JMa, 2003, Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity, Toxicon, 42, 915, 10.1016/j.toxicon.2003.11.005 · DOI · Paper page
- Serrano, 2005, Snake venom serine proteinases: sequence homology vs. substrate specificity, a paradox to be solved, Toxicon, 45, 1115, 10.1016/j.toxicon.2005.02.020 · DOI · Paper page
- Williams, 2019, Mechanisms underpinning the permanent muscle damage induced by snake venom metalloprotease, PLoS Neglected Trop Dis, 13, 10.1371/journal.pntd.0007041 · DOI
- Lewin, 2016, Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation, Toxins, 8, 248, 10.3390/toxins8090248 · DOI · Paper page
- Abraham, 2003, Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure, Crit Care Med, 31, 718, 10.1097/01.CCM.0000053648.42884.89 · DOI
- Bryan-Quirós, 2019, Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2, Toxicon, 157, 1, 10.1016/j.toxicon.2018.11.292 · DOI · Paper page
- King, 2003, Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects, Anticancer Res, 23, 639
- Howes, 2007, Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators, Toxicon, 49, 734, 10.1016/j.toxicon.2006.11.020 · DOI
- Shaposhnik, 2009, The synergistic inhibition of atherogenesis in apoE−/− mice between pravastatin and the sPLA2 inhibitor varespladib (A-002), J Lipid Res, 50, 623, 10.1194/jlr.M800361-JLR200 · DOI
- Rosenson, 2009, Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial, Lancet, 373, 649, 10.1016/S0140-6736(09)60403-7 · DOI
- Nicholls, 2014, Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial, JAMA, 311, 252, 10.1001/jama.2013.282836 · DOI · Paper page
- Gutierrez, 2007, Trends in snakebite envenomation therapy: scientific, technological and public health considerations, Curr Pharm Des, 13, 2935, 10.2174/138161207782023784 · DOI · Paper page
- Curran, 1999, Matrix metalloproteinases in tumour invasion and metastasis, J Pathol, 189, 300, 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C · DOI · Paper page
- Rasmussen, 1997, Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat, Pharmacol Ther, 75, 69, 10.1016/S0163-7258(97)00023-5 · DOI · Paper page
- Underwood, 2003, The interaction of metal ions and marimastat with matrix metalloproteinase 9, J Inorg Biochem, 95, 165, 10.1016/S0162-0134(03)00100-4 · DOI
- Zhang, 1994, Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d), Proc Natl Acad Sci, 91, 8447, 10.1073/pnas.91.18.8447 · DOI · Paper page
- Nagase, 1999, Matrix metalloproteinases, J Biol Chem, 274, 21491, 10.1074/jbc.274.31.21491 · DOI · Paper page
- Steward, 2000, Marimastat: the clinical development of a matrix metalloproteinase inhibitor, Expet Opin Invest Drugs, 9, 2913, 10.1517/13543784.9.12.2913 · DOI
- Albulescu, 2020, A combination of two small molecule toxin inhibitors provides pancontinental preclinical efficacy against viper snakebite, bioRxiv
- Takeda, 2012, Snake venom metalloproteinases: structure, function and relevance to the mammalian ADAM/ADAMTS family proteins, Biochim Biophys Acta Protein Proteonomics, 1824, 164, 10.1016/j.bbapap.2011.04.009 · DOI · Paper page
- Wax, 2013, Current use of chelation in American health care, J Med Toxicol, 9, 303, 10.1007/s13181-013-0347-2 · doi:10.1007/s13181-013-0347-2
- Lawson, 2016, Chelators in iron and copper toxicity, Curr Pharmacol Rep, 2, 271, 10.1007/s40495-016-0068-8 · DOI
- Urs, 2015, Inhibitory potential of three zinc chelating agents against the proteolytic, hemorrhagic, and myotoxic activities of Echis carinatus venom, Toxicon, 93, 68, 10.1016/j.toxicon.2014.11.224 · doi:10.1016/j.toxicon.2014.11.224
- Peters, 1945, British anti-lewisite (BAL), Nature, 156, 616, 10.1038/156616a0 · DOI · Paper page
- Verma, 2010, Accidental inorganic mercury chloride poisoning in a 2-year old child, Indian J Pediatr, 77, 1153, 10.1007/s12098-010-0143-9 · DOI
- Kathirgamanathan, 2013, Cardiac conduction block at multiple levels caused by arsenic trioxide therapy, Can J Cardiol, 29
- Ioannou, 2018, Interaction of British anti-lewisite (BAL) with copper (I) and copper (II) compounds in conjunction with Wilson's disease, Main Group Chem, 17, 1, 10.3233/MGC-180246 · doi:10.3233/mgc-180246
- Still, 2017, Multipurpose HTS coagulation analysis: assay development and assessment of coagulopathic snake venoms, Toxins, 9, 382, 10.3390/toxins9120382 · DOI
- Slagboom, 2020, High throughput screening and identification of coagulopathic snake venom proteins and peptides using nanofractionation and proteomics approaches, PLoS Neglected Trop Dis, 14, 10.1371/journal.pntd.0007802 · DOI
- Xie, 2020, Antivenom neutralization of coagulopathic snake venom toxins assessed by bioactivity profiling using nanofractionation analytics, Toxins, 12, 53, 10.3390/toxins12010053 · DOI
- Otero-Patiño, 2009, Epidemiological, clinical and therapeutic aspects of Bothrops asper bites, Toxicon, 54, 998, 10.1016/j.toxicon.2009.07.001 · DOI · Paper page
- Mora Rodríguez, 2008, Effects of Bothrops asper snake venom on lymphatic vessels: insights into a hidden aspect of envenomation, PLoS Neglected Trop Dis, 2, e318, 10.1371/journal.pntd.0000318 · DOI · Paper page
- Yamashita, 2014, Bothrops jararaca venom metalloproteinases are essential for coagulopathy and increase plasma tissue factor levels during envenomation, PLoS Neglected Trop Dis, 8, 10.1371/journal.pntd.0002814 · DOI
- Tang, 2016, Venomics of Calloselasma rhodostoma, the Malayan pit viper: a complex toxin arsenal unraveled, J Proteomics, 148, 44, 10.1016/j.jprot.2016.07.006 · DOI
- Chen, 2019, Snake venom proteome and immuno-profiling of the hundred-pace viper, Deinagkistrodon acutus, in Taiwan, Acta Trop, 189, 137, 10.1016/j.actatropica.2018.09.017 · DOI
- Kraisawat, 2020, Duration after Malayan pit viper bite to detect coagulopathy in Songklanagarind hospital, J Health Sci Med Res, 38, 93
- Su, 2018, Clinical and laboratory features distinguishing between Deinagkistrodon acutus and Daboia siamensis envenomation, J Venom Anim Toxins Incl Trop Dis, 24, 43, 10.1186/s40409-018-0179-2 · doi:10.1186/s40409-018-0179-2
- Bustillo, 2015, Phospholipase A2 enhances the endothelial cell detachment effect of a snake venom metalloproteinase in the absence of catalysis, Chem Biol Interact, 240, 30, 10.1016/j.cbi.2015.08.002 · DOI · Paper page
- Bustillo, 2012, Synergism between baltergin metalloproteinase and Ba SPII RP4 PLA2 from Bothrops alternatus venom on skeletal muscle (C2C12) cells, Toxicon, 59, 338, 10.1016/j.toxicon.2011.11.007 · DOI
- Montecucco, 2008, Cellular pathology induced by snake venom phospholipase A2 myotoxins and neurotoxins: common aspects of their mechanisms of action, Cell Mol Life Sci, 65, 2897, 10.1007/s00018-008-8113-3 · DOI · Paper page
- Lomonte, 2011, Phospholipases A2 from viperidae snake venoms: how do they induce skeletal muscle damage?., Acta Chim Slov, 58, 647
- Lewin, 2018, Delayed LY333013 (oral) and LY315920 (intravenous) reverse severe neurotoxicity and rescue juvenile pigs from lethal doses of Micrurus fulvius (Eastern coral snake) venom, Toxins, 10, 479, 10.3390/toxins10110479 · DOI · Paper page
Cited by
Smith, C. F., Modahl, C. M., Ceja Galindo, D., Larson, K. Y., Maroney, S. P., Bahrabadi, L., Brandehoff, N. P., Perry, B. W., McCabe, M. C., Petras, D., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100779 · Cited by 11
Metadata
- Authors
- Xie, C., Slagboom, J., Albulescu, L.-O., Somsen, G. W., Vonk, F. J., Casewell, N. R., & Kool, J.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 10
- Issue
- 10
- Pages
- 1835-1845
- ISSN
- 2211-3835
- Cited by
- 35
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Medical Research Council (200517/Z/16/Z, CiC19017, MR/S00016X/1)
- Royal Society
- China Scholarship Council (201706250035)
- Wellcome Trust
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neutralising effects of small molecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake venoms. https://app.cochat.ai/papers/10.1016/j.apsb.2020.09.005
- The paper
- Xie, C., Slagboom, J., Albulescu, L.-O., Somsen, G. W., Vonk, F. J., Casewell, N. R., & Kool, J. (2020). Neutralising effects of small molecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake venoms. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2020.09.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.